News and Comments

Regulus Offers Proof of Concept and Feasibility with Its HCV RNA Targeted Drug

  Wednesday, February 17, 2016

Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one of the company's ongoing Phase 2 studies of its hepatitis C virus (HCV) product RG-101.   More...

Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm

  Friday, February 05, 2016

Gilead Sciences More...

Dana-Farber Institute and Array Pharmaceutical Scientists to Work Together

  Tuesday, February 02, 2016

Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications.    More...

Exelixis has Good News About CABO

  Thursday, January 28, 2016


The Two Pianists. Breakthrough in the Diagnosis and Treatment of Diseases. See also Illumina

  Monday, January 11, 2016

The Evolution of Liquid Biopsy More...

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

  Monday, January 04, 2016

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. There will be many explanations like usual, but it is difficult for us to speculate this time over the correctness of the offered explanations, including the Iran Saudi Arabia crisis, which led to an increase in the oil price whose decrease has caused the previous market’s bad mood.    More...

ARRAY Rallies On Successful NEMO trial Results Of Binetinib on NRAS-Mutant Melanoma

  Wednesday, December 16, 2015

When you do your due diligence, you do not lose your faith in what you believed in giving up to the hype that’s sprayed around you. We were happy today to hear Array BioPharma (ARRY) report that results from the Phase 3 NEMO clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma. The trial met its primary endpoints.  More...

Halozyme PEGPH20 Improves the Efficacy of Halavan In Triple Negative Breast Cancer

  Thursday, December 10, 2015

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin Mesylate (HALAVEN®) in Triple Negative Breast Cancer Xenografts" at the 38th Annual San Antonio Breast Cancer Symposium (SABCS).   More...

XOMA: Good News for the Firm We Love and Hate But We Never Divorce

  Wednesday, December 02, 2015

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes  More...

BIOMARIN: What Happened During the FDA Committee Meeting?

  Wednesday, November 25, 2015


Recent Postings



Elan (ELN) Vitae Pharmaceuticals (VTAE) Pluristem (PSTI) BIOMARIN (BMRN) Onyx (ONXX) CRISPR Therapeutics (CRSP) JUNO (JUNO) Tysabri Prosensa (RNA) Global Cell Therapeutics (GBT) Telaprevir Sangamo (SGMO) Inovio (INO) Human Genome Sciences (HGSI) Herceptin ARCA (ABIO) TOKAI (TKAOI) ARGOS (ARGS) Prolor Biotech (PBTH) Gilead (GILD) CompuGen (CGEN) Intrexon (XON) Idenix (IDIX) RenenxBio (RGNX) Adaptimmune (ADAP) Spike Therapeutics (ONCE) Zerenex VANDA (VNDA) Regeneron (REGN) Jazz Pharmaceuticals (JAZZ) Sanofi (SNA) Benlysta (belimumab) Editas (EDIT) SERES THERAPEUTICS (MCRB) AstraZeneca (AZN) Micromet (MITI) Theravance Bio Pharma (TBPH) Ziofpharm (ZIOP) Merck (MRK) SUNESIS PHARMACEUTICALS (SNSS) C4 Therapeutics Abbott Laboratories (ABT) Genentech Dynavax (DVAX) KITE (KITE) ABBVIE (ABBV) Ocular Therapeutix (OCUL) Sanofi (SNY) Auspex (ASPX) PTC Therapeutics (PTCT) INNOVIVA (INVA) ACADIA (ACAD) galapagos (GLPG) KERYX (KERX) Exelixis (EXEL) Cytokinetics (CYTK) NOVOCURE (NVCR) Anadys (ANDS) Incyte (INCY) MODERNA Xoma (XOMA) ImmunoGen (IMGN) Sequenom (SQNM) Intercept (ICPT) Sanofi-Aventis (SAN) AERIE PHARMACEUTICALS Bristol-Myers Squibb (BMY) NANTKWEST (NK) Alder Biopharmaceuticals (ALDR) REGULUS (RGLS) SYNTA (SNTA) Sarepta (SRPT) Vertex (VRTX) Roche (RHHBY) Alnylam (ALNY) OSI (OSIP) Anacor (ANAC) Galena (GALE) NEKTAR (NKTR)) ZALTRAP™ Seattle Genetics (SGEN) Rapamune Illumina (ILMN) GUARDIAN HEALTH Valeant Pharmaceuticals International (VRX) Endometrial Cancer Array Pharmaceuticals (ARRY) Ionis (IONS) Biocryst (BCRX) Mirati Therapeutics (MRTX) ADVENTRIX (ANX) Velcade (bortezomib) Human Longevity (HLI) Dendreon (DNDN) ISIS (ISIS) Biogen Idec (BIIB) Intermune (ITMN) Agenus (AGEN) Revlimid (lenolidamide) Roche (ROCHE) Theravance (THRX) HALOZYME (HALO) Advaxis (ADXS) Amgen (AMGN) IDERA (IDRA) GlaxoSmithKline (GSK) Ridaforolimus Agenus (AGEN Aimmune Therapeutics (AIMT) Ariad (ARIA) Trastuzumab-DM1 Multiple Myeloma Bellicum (BLCM) AGOS (ARGS)